Decision Making in Proliferative Diabetic Retinopathy Treatment
- 45 Downloads
Purpose of Review
The goal of this paper is to provide a comprehensive review of the recent advances in the management options for proliferative diabetic retinopathy.
For many years, cases of proliferative diabetic retinopathy (PDR) have been managed by pan retinal photocoagulation (PRP). The advent of anti-vascular endothelial growth factor (anti-VEGF) agents has changed the future of PDR management and has provided an alternative to PRP.
Management of PDR requires the identification of high-risk characteristics for PDR and the decision regarding the most appropriate treatment modality. The risk to benefit ratio for each treatment modality must be considered in determining the appropriate choice between surgical intervention (PRP) versus medical intervention with anti-VEGF.
KeywordsProliferative diabetic retinopathy Vascular endothelial growth factor Anti-VEGF Pan retinal photocoagulation Intravitreal injection Ranibizumab Bevacizumab Aflibercept
The editors thank Dr. Fernando Penha for lending his expertise and reviewing this manuscript.
This study is supported by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Clinical Sciences Research EPID-006-15S, NIH Center Core Grant P30EY014801, and Research to Prevent Blindness Unrestricted Grant.
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 7.Kobayashi et al. Vitreous levels of vascular endothelial growth factor in eyes with anterior hyaloidal fibrovacular proliferation. Clin Ophthalmol. 2010;4:1043–6.Google Scholar
- 19.Early Treatment Diabetic Retinopathy Study Research Group. Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Ophthalmology. 1991;98(5 suppl):766–85.Google Scholar
- 23.Marshall J, Clover G, Rothery S. Some new findings on retinal irradiation by krypton and argon lasers. Doc Ophthalmol Proc Ser. 1984;36:21–37.Google Scholar
- 27.Googe J, Brucker AJ, Bressler NM, Diabetic Retinopathy Clinical Research Network, et al. Randomized trial evaluating short-term effects of intravitreal ranibizumab or triamcinolone acetonide on macular edema after focal/grid laser for diabetic macular edema in eyes also receiving panretinal photocoagulation. Retina. 2011;31(6):1009–27.CrossRefPubMedGoogle Scholar
- 43.•• Gross JG, Glassman AR, Liu D, et al. Five-Year outcomes of panretinal photocoagulation vs intravitreal ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial. JAMA Ophthalmol. 2018. https://doi.org/10.1001/jamaophthalmol.2018.3255 This follow up study allowed the reader to observe how the primary outcome seen at 2 years was upheld, as well as allowed the observation of additional outcome measures regarding the use of intravitreal ranibizumab vs PRP for PDR.
- 49.• Hutton DW, Stein JD, Bressler NM, et al. Cost-effectiveness of intravitreous ranibizumab compared with panretinal photocoagulation for proliferative diabetic retinopathy. JAMA Ophthalmol. 2017;135(6):576–84 This study outlines the cost analysis of the 2-year Protocol S data in comparing the use of ranibizumab vs PRP for DME.CrossRefPubMedPubMedCentralGoogle Scholar
- 50.• Lin J, Chang JS, Yannuzzi NA, Smiddy WE. Cost evaluation of early vitrectomy versus panretinal photocoagulation and intravitreal ranibizumab for proliferative diabetic retinopathy. Ophthalmology. 2018;125(9):1393–400 This study suggests that the cost utility of PPV vs PRP is similar and that PPV has a more favorable cost utility as compared to ranibizumab.CrossRefPubMedGoogle Scholar